公开(公告)号：US20210347773A1

公开(公告)日：2021-11-11

申请号：US17328814

申请日：2021-05-24

Applicant: ONO PHARMACEUTICAL CO., LTD. ,  VANDERBILT UNIVERSITY

Inventor： Craig W. LINDSLEY ,  Joshua M. WIETING ,  Kevin M. MCGOWAN ,  Jerod S. DENTON ,  Kentaro YASHIRO ,  Haruto KURATA ,  Yoko SEKIOKA ,  Takahiro MORI ,  Yuzo IWAKI

IPC: C07D471/04 ,  C07C255/57 ,  C07C317/28 ,  C07D209/30 ,  C07D213/89 ,  C07D231/56 ,  C07D235/16 ,  C07D237/24 ,  C07D239/47 ,  C07D249/08 ,  C07D249/18 ,  C07D257/04 ,  C07D265/36 ,  C07D271/10 ,  C07D285/14 ,  C07D295/04 ,  C07D401/04 ,  C07D513/04

Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

公开(公告)号：US20140023636A1

公开(公告)日：2014-01-23

申请号：US14033972

申请日：2013-09-23

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Hiromu HABASHITA ,  Haruto KURATA ,  Shinji NAKADE

IPC: C07D471/04 ,  A61K31/397 ,  A61K45/06 ,  C07F5/02 ,  A61K31/69 ,  A61K31/437 ,  C07D205/04 ,  C07D409/06

CPC classification number: C07F5/027 ,  A61K31/12 ,  A61K31/166 ,  A61K31/197 ,  A61K31/215 ,  A61K31/397 ,  A61K31/4035 ,  A61K31/41 ,  A61K31/437 ,  A61K31/4409 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/4725 ,  A61K31/55 ,  A61K31/69 ,  A61K45/06 ,  C07C229/14 ,  C07C2602/10 ,  C07D205/04 ,  C07D211/70 ,  C07D271/06 ,  C07D401/12 ,  C07D409/06 ,  C07D471/04 ,  A61K2300/00

Abstract: The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. wherein all symbols are described in the specification.

Abstract translation: 本发明涉及由式（I）表示的化合物，其盐，其N-氧化物形式，其溶剂化物或其前药，以及含有该化合物的药物。 由式（I）表示的化合物具有与S1P受体（特别是EDG-1，EDG-6和/或EDG-8）结合的能力，并且可用于预防和/或治疗移植排斥反应， 移植物抗宿主病，自身免疫性疾病，过敏性疾病，神经变性疾病等。 其中所有符号在说明书中描述。

公开(公告)号：US20190322662A1

公开(公告)日：2019-10-24

申请号：US16470196

申请日：2017-12-14

Applicant: ONO PHARMACEUTICAL CO., LTD. ,  Vanderbilt University

Inventor： Craig W LINDSLEY ,  Joshua M. WIETING ,  Kevin M. MCGOWAN ,  Jerod S. DENTON ,  Kentaro YASHIRO ,  Haruto KURATA ,  Yoko SEKIOKA ,  Takahiro MORI ,  Yuzo IWAKI

IPC: C07D471/04 ,  C07C317/28 ,  C07D231/56 ,  C07D249/08 ,  C07D213/89 ,  C07D239/47 ,  C07D237/24 ,  C07D235/16 ,  C07D249/18 ,  C07D285/14 ,  C07D401/04 ,  C07C255/57 ,  C07D265/36 ,  C07D209/30 ,  C07D271/10 ,  C07D257/04 ,  C07D295/04 ,  C07D513/04

Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.

公开(公告)号：US20240190824A1

公开(公告)日：2024-06-13

申请号：US17769300

申请日：2020-10-23

Applicant: ONO PHARMACEUTICAL CO., LTD. ,  VANDERBILT UNIVERSITY

Inventor： Craig W LINDSLEY ,  Darren W ENGERS ,  Elizabeth S CHILDRESS ,  Sean R BOLLINGER ,  Joza SCHMITT ,  Trevor C CHOPKO ,  Jerod S DENTON ,  Motoyuki TANAKA ,  Haruto KURATA

IPC: C07D213/75 ,  C07D241/20 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/12

CPC classification number: C07D213/75 ,  C07D241/20 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/12

Abstract: Disclosed is a compound of formula (I): in which all symbols are defined in the description. Also disclosed are pharmaceutical compositions including the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.

公开(公告)号：US20170327439A1

公开(公告)日：2017-11-16

申请号：US15532389

申请日：2014-12-03

Applicant: ONO PHARMACEUTICAL CO., LTD.

Inventor： Kensuke KUSUMI ,  Haruto KURATA ,  Atsushi NAGANAWA ,  Yasuyo KODERA ,  Yuichi INAGAKI ,  Hiroya TAKIZAWA ,  Mark Allan WOLF ,  Joseph RAKER

IPC: C07C13/48 ,  C07D205/04 ,  A61K31/397 ,  A61K31/19 ,  A61K31/015 ,  C07D401/10 ,  C07C13/20 ,  C07C2602/10

CPC classification number: C07C13/48 ,  A61K31/015 ,  A61K31/19 ,  A61K31/397 ,  C07C13/20 ,  C07C2602/10 ,  C07D205/04 ,  C07D207/16 ,  C07D401/10 ,  C07D403/10

Abstract: A compound represented by general formula (I) (wherein, all the symbols are as defined in the specification) has a selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; .i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for treating S1P5-mediated disease, e.g., neurodegenerative disease such as schizophrenia.